ANEBULO PHARMACEUTICALS, INC. Deferred Offering Costs
ANEBULO PHARMACEUTICALS, INC. (ANEB) had Deferred Offering Costs of $0 as of 2024-06-30, per its 10-K filed 2024-09-25.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2024-09-25
- 2024-06-30: Deferred Offering Costs $0.00.
- 2023-06-30: Deferred Offering Costs $0.00.
- 2022-06-30: Deferred Offering Costs $0.00.
- 2021-06-30: Deferred Offering Costs $0.00.
| Period end | Deferred Offering Costs |
|---|---|
| 2024-06-30 | $0.00 10-K · filed 2024-09-25 |
| 2023-06-30 | $0.00 10-K · filed 2024-09-25 |
| 2022-06-30 | $0.00 10-K · filed 2023-09-22 |
| 2021-06-30 | $0.00 10-K · filed 2022-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |